Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

033270.KS

STRONG BUYREMOVE

Korea United Pharm Inc. · Healthcare · South Korea · $166M · Avg Vol: $334K/d

91
StockRank
Q
65
V
78
M
40
P/E (TTM)
6.5x
ROE
12.2%
D/E
0.1x
Dividend %
3.6%
Director Trades · 180d
None in 180d →
Buybacks · 180d
None in 180d →
AI CONVICTION THESIS

Korea United Pharm is a small-cap specialty generic drug manufacturer lacking the scale, proprietary platforms, or global CDMO capabilities required to benefit from the CDMO pricing power cycle.

COMPANY DESCRIPTION

Korea United Pharm Inc. is a specialty pharmaceutical company focused on the research, development, and manufacturing of generic and incrementally modified drugs (IMDs). The company's competitive moat lies in its proprietary formulation technologies, which allow it to develop high-margin IMDs with improved efficacy and reduced side effects. It operates as a niche market leader in South Korea while actively expanding its export portfolio to over 40 countries.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGR
Revenue171.0M181.7M188.0M188.1M3.2%
EPS1.992.151.441.70-5.1%
Shares16.2M16.2M16.3M16.3M+0.5%
Debt19.7M26.3M10.2M9.1M-22.6%
Equity220.0M246.6M264.5M296.1M10.4%
Op CF41.5M32.4M17.4M33.3M-7.1%
Inv CF-57.2M-36.2M7.6M-26.7M—
Fin CF-6.9M1.7M-19.2M-2.4M—
Loading...
PRICE (1Y)-16.8%
10.7611.3011.8412.3812.93May 14Jun 8Jun 26
SMA 50SMA 200
Close
$10.76
RSI (14)
36.3
52W High
$14.20
From 52W High
0.8%

SCORE BREAKDOWN

Quality
65
ROIC
10.6%75.1
ROE
12.2%77.0
GP/Assets
16.2%37.6
Op. Margin
9.9%66.0
FCF/Assets
2.2%58.1
Piotroski
782.3
Int. Cover
50.0x88.5
D/E Ratio
0.14x60.6
Current Ratio
3.75x62.1
Value
78
P/E (TTM)
6.5x95.2
EV/EBITDA
8.4x75.7
P/FCF
22.2x54.1
P/B
0.6x93.6
P/S
1.5x74.9
Div Yield
3.6%77.4
Momentum
40
52W High %
76%69.0
RS 6M
-120%7.2
SMA 50/200
1.00x63.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
-7%34.6

FUNDAMENTALS

Market Cap
$166M
P/E (Forward)
6.4x
Gross Margin
52.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 033270.KS are excluded.

TickerCompanyMkt CapStockRankSignal
033270.KSKorea United Pharm Inc.(you)$166M91STRONG BUY
001630.KSChong Kun Dang Holdings Corp.$124M91STRONG BUY
005500.KSSamjin Pharmaceuticals Co., Ltd.$153M96STRONG BUY
016580.KSWhan In Pharm Co.,Ltd.$118M92STRONG BUY
096760.KSJW Holdings Corporation$166M100STRONG BUY
023910.KQDaihan Pharmaceutical Co.,Ltd.$96M90STRONG BUY
234080.KSJW Lifescience Corporation$113M97STRONG BUY
243070.KQHuons Co., Ltd.$210M80STRONG BUY
008490.KSSuheung Co., Ltd.$132M79BUY
000640.KSDong-A Socio Holdings Co., Ltd.$331M85STRONG BUY

Peer medians: ROE 0.1% · P/E 16.8x · Gross margin 43.8%

Korea United Pharm Inc. (033270.KS) — Stock Score Summary

Korea United Pharm Inc. (033270.KS) has a MoatMap StockRank of 91/100 based on Quality (65/100), Value (78/100), and Momentum (40/100) factor scores. The current signal is STRONG BUY. Korea United Pharm is a small-cap specialty generic drug manufacturer lacking the scale, proprietary platforms, or global CDMO capabilities required to benefit from the CDMO pricing power cycle.

Korea United Pharm Inc. is a specialty pharmaceutical company focused on the research, development, and manufacturing of generic and incrementally modified drugs (IMDs). The company's competitive moat lies in its proprietary formulation technologies, which allow it to develop high-margin IMDs with improved efficacy and reduced side effects. It operates as a niche market leader in South Korea while actively expanding its export portfolio to over 40 countries.

Key Financial Metrics

Price$10.76
Market Cap$166M
P/E (TTM)6.51
P/E (Forward)6.41
Price/Book0.61
Return on Equity12.2%
Return on Invested Capital10.6%
Debt/Equity13.85
Gross Margin52.5%
Operating Margin9.9%
Revenue Growth6.1%
Dividend Yield3.6%
Free Cash Flow$7M

Korea United Pharm Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (South Korea).

Frequently Asked Questions

What is Korea United Pharm Inc.’s (033270.KS) StockRank?
MoatMap’s StockRank for Korea United Pharm Inc. (033270.KS) is 91/100, with a Strong Buy signal. It is a composite of Quality (65), Value (78), and Momentum (40) factor ranks across MoatMap’s 20,000+ stock universe.
Does Korea United Pharm Inc. have an economic moat?
Korea United Pharm Inc. (033270.KS) has a Quality factor score of 65/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Korea United Pharm Inc. a buy, hold, or sell?
MoatMap’s current signal for Korea United Pharm Inc. (033270.KS) is Strong Buy, based on a StockRank of 91/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Korea United Pharm Inc. in?
Korea United Pharm Inc. (033270.KS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (South Korea).
Browse all ranked stocks033270.KS deep dive reportAI ChampionsHow we score stocksSense-check another stock